Previous 10 | Next 10 |
2024-01-05 09:00:00 ET Summary ABBV's Humira erosion has been well balanced by the robust growth reported by Skyrizi and Rinvoq, implying its ability to maintain a stable top/ bottom line performance ahead. The management has also participated in the aggressive M&A activities ...
NEW YORK, NY / ACCESSWIRE / January 4, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: RayzeBio, Inc. (NASDAQ:RYZB)'s sale ...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2024-01-01 15:37:15 ET More on AbbVie, Bristol-Myers Squibb Company , etc. Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation Bristol Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Management Bristol Myers Squibb: Aggress...
NEW YORK, NY / ACCESSWIRE / December 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Summit Materials, Inc. (NYSE:SUM)'s ...
2023-12-24 09:11:28 ET More on Bristol-Myers Squibb Company , Karuna Therapeutics, etc. Bristol-Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge Bristol Myers...
2023-12-23 04:18:53 ET Summary AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth potential. GSK's current financials, product la...
2023-12-14 11:34:23 ET Acadia Pharmaceuticals: Legal Overhang On Nuplazid Removed Acadia's Daybue: A Small Patient Pool Making Big Waves ACADIA Pharmaceuticals Inc. (ACAD) Q3 2023 Earnings Call Transcript Acadia Pharmaceuticals surges 32% after win in patent suit...
NEW YORK, NY / ACCESSWIRE / December 11, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, In...
NEW YORK, NY / ACCESSWIRE / December 9, 2023/ Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cerevel Therapeutics Holdings, I...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are enco...